NR4A1 and breast cancer: In a study predicting PAM50 expression-based molecular subtypes from breast cancer WSIs, Jaber et al. were able to show that tumours predicted as heterogeneous had survival intermediate between Luminal A and Basal patients, as well as more varied levels of hormone receptor expression patterns [55].